BCM
APRE icon

Bridgeway Capital Management’s Aprea Therapeutics APRE Stock Holding History

Bridgeway Capital Management’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,000
Closed -$13K – 1372
2022
Q3 		$13K Sell
1,000
-1,250
-56% -$22.2K ﹤0.01% 1398
2022
Q2 		$33K Sell
2,250
-750
-25% -$17.3K ﹤0.01% 1302
2022
Q1 		$112K Sell
3,000
-750
-20% -$30.7K ﹤0.01% 1250
2021
Q4 		$215K Hold
3,750
– – ﹤0.01% 1154
2021
Q3 		$383K Buy
+3,750
New +$341K 0.01% 1110

Other funds holding APRE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bridgeway Capital Management's APRE Position: Q4 2022 in Review

Bridgeway Capital Management sold out of Aprea Therapeutics (APRE) in Q4 2022, closing a stake of 1,000 shares — an estimated $13K sold.

Bridgeway Capital Management first reported a position in APRE in Q3 2021 and held it in 5 quarters. The position peaked at $383K in Q3 2021. 24 funds tracked by Wall St. Rank hold APRE as of Q4 2022.

  • Bridgeway Capital Management reported no remaining Aprea Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Bridgeway Capital Management sold 1,000 Aprea Therapeutics shares in Q4 2022, an estimated $13K.
  • Bridgeway Capital Management first reported a position in Aprea Therapeutics in Q3 2021 and held it in 5 quarters.
  • Bridgeway Capital Management's Aprea Therapeutics position peaked at $383K in Q3 2021.
  • 24 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q4 2022.

Based on Bridgeway Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.